Tags

Type your tag names separated by a space and hit enter

The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Respir Med. 2017 06; 127:57-64.RM

Abstract

RATIONALE

Anti-aminoacyl transfer RNA synthetase antibodies (anti-ARS) are a group of myositis-specific autoantibodies that are detected in the sera of patients with polymyositis and dermatomyositis (PM/DM) and also in those of patients with idiopathic interstitial pneumonias without any connective tissue disease (CTD), including PM/DM. Although we reported the clinical characteristics of interstitial lung disease with anti-ARS antibodies (ARS-ILD) with and without PM/DM, the long-term prognosis of ARS-ILD remains undetermined. As our previous studies revealed that ARS-ILD without PM/DM was similar to CTD-associated ILD, and that ARS-ILD with PM/DM was radiologically suggestive of a nonspecific interstitial pneumonia (NSIP) pathological pattern, we hypothesized that the prognosis of ARS-ILD might be distinct from that of idiopathic pulmonary fibrosis (IPF) without anti-ARS.

OBJECTIVES

To elucidate the long-term outcome of ARS-ILD with and without PM/DM and compare it to that of IPF.

METHODS

A two-center retrospective study was conducted. The study population comprised 36 patients with ARS-ILD (8 with PM, 12 with DM, and 16 without myositis throughout the course), 100 patients with IPF without anti-ARS, and 7 patients with NSIP without anti-ARS. The presence of anti-ARS was determined by RNA immunoprecipitation using the sera obtained at the time of diagnosis before specific treatment.

MEASUREMENTS AND MAIN RESULTS

During the observational period (median 49 months; range, 1-114 months), 7 patients with ARS-ILD (19%; 3 with PM, 1 with DM, and 3 without PM/DM) and 51 patients with IPF (51%) died. Patients with ARS-ILD had better overall survival than those with IPF (log-rank test, P < 0.001) and similar survival compared to those with NSIP (log-rank test, P = 0.59). The prognosis for patients with ARS-ILD was similar between those with and without myositis (log-rank test, P = 0.91). At the median follow-up time of 76.5 months, 14 of the 36 patients with ARS-ILD had deteriorated. Both a decline in forced vital capacity or an initiation of long-term oxygen therapy during the course (odds ratio [OR], 5.34) and acute exacerbation (OR, 28.4) significantly increased the mortality risk.

CONCLUSIONS

The long-term outcome of ARS-ILD was significantly better than that of IPF regardless of the presence or absence of myositis.

Authors+Show Affiliations

Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: hanta@kuhp.kyoto-u.ac.jp.Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Fukui Red-Cross Hospital, Fukui, Japan.Department of Respiratory Medicine, Saiseikai Noe Hospital, Osaka, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Tenri Hospital, Tenri, Japan.Department of Rheumatology, Tenri Hospital, Tenri, Japan.Department of Radiology, Tenri Hospital, Tenri, Japan.Department of Pathology, Tenri Hospital, Tenri, Japan.Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Kyoto Central Clinic, Clinical Research Center, Kyoto, Japan.Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

28461123

Citation

Tanizawa, Kiminobu, et al. "The Long-term Outcome of Interstitial Lung Disease With anti-aminoacyl-tRNA Synthetase Antibodies." Respiratory Medicine, vol. 127, 2017, pp. 57-64.
Tanizawa K, Handa T, Nakashima R, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57-64.
Tanizawa, K., Handa, T., Nakashima, R., Kubo, T., Hosono, Y., Watanabe, K., Aihara, K., Ikezoe, K., Sokai, A., Nakatsuka, Y., Taguchi, Y., Hatta, K., Noma, S., Kobashi, Y., Yoshizawa, A., Oga, T., Hirai, T., Chin, K., Nagai, S., ... Mishima, M. (2017). The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respiratory Medicine, 127, 57-64. https://doi.org/10.1016/j.rmed.2017.04.007
Tanizawa K, et al. The Long-term Outcome of Interstitial Lung Disease With anti-aminoacyl-tRNA Synthetase Antibodies. Respir Med. 2017;127:57-64. PubMed PMID: 28461123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. AU - Tanizawa,Kiminobu, AU - Handa,Tomohiro, AU - Nakashima,Ran, AU - Kubo,Takeshi, AU - Hosono,Yuji, AU - Watanabe,Kizuku, AU - Aihara,Kensaku, AU - Ikezoe,Kohei, AU - Sokai,Akihiko, AU - Nakatsuka,Yoshinari, AU - Taguchi,Yoshio, AU - Hatta,Kazuhiro, AU - Noma,Satoshi, AU - Kobashi,Yoichiro, AU - Yoshizawa,Akihiko, AU - Oga,Toru, AU - Hirai,Toyohiro, AU - Chin,Kazuo, AU - Nagai,Sonoko, AU - Izumi,Takateru, AU - Mimori,Tsuneyo, AU - Mishima,Michiaki, Y1 - 2017/04/15/ PY - 2016/11/12/received PY - 2017/04/11/revised PY - 2017/04/13/accepted PY - 2017/5/4/pubmed PY - 2018/2/27/medline PY - 2017/5/3/entrez KW - Autoantibodies KW - Connective tissue diseases KW - Idiopathic pulmonary fibrosis KW - Myositis KW - Survival SP - 57 EP - 64 JF - Respiratory medicine JO - Respir Med VL - 127 N2 - RATIONALE: Anti-aminoacyl transfer RNA synthetase antibodies (anti-ARS) are a group of myositis-specific autoantibodies that are detected in the sera of patients with polymyositis and dermatomyositis (PM/DM) and also in those of patients with idiopathic interstitial pneumonias without any connective tissue disease (CTD), including PM/DM. Although we reported the clinical characteristics of interstitial lung disease with anti-ARS antibodies (ARS-ILD) with and without PM/DM, the long-term prognosis of ARS-ILD remains undetermined. As our previous studies revealed that ARS-ILD without PM/DM was similar to CTD-associated ILD, and that ARS-ILD with PM/DM was radiologically suggestive of a nonspecific interstitial pneumonia (NSIP) pathological pattern, we hypothesized that the prognosis of ARS-ILD might be distinct from that of idiopathic pulmonary fibrosis (IPF) without anti-ARS. OBJECTIVES: To elucidate the long-term outcome of ARS-ILD with and without PM/DM and compare it to that of IPF. METHODS: A two-center retrospective study was conducted. The study population comprised 36 patients with ARS-ILD (8 with PM, 12 with DM, and 16 without myositis throughout the course), 100 patients with IPF without anti-ARS, and 7 patients with NSIP without anti-ARS. The presence of anti-ARS was determined by RNA immunoprecipitation using the sera obtained at the time of diagnosis before specific treatment. MEASUREMENTS AND MAIN RESULTS: During the observational period (median 49 months; range, 1-114 months), 7 patients with ARS-ILD (19%; 3 with PM, 1 with DM, and 3 without PM/DM) and 51 patients with IPF (51%) died. Patients with ARS-ILD had better overall survival than those with IPF (log-rank test, P < 0.001) and similar survival compared to those with NSIP (log-rank test, P = 0.59). The prognosis for patients with ARS-ILD was similar between those with and without myositis (log-rank test, P = 0.91). At the median follow-up time of 76.5 months, 14 of the 36 patients with ARS-ILD had deteriorated. Both a decline in forced vital capacity or an initiation of long-term oxygen therapy during the course (odds ratio [OR], 5.34) and acute exacerbation (OR, 28.4) significantly increased the mortality risk. CONCLUSIONS: The long-term outcome of ARS-ILD was significantly better than that of IPF regardless of the presence or absence of myositis. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/28461123/The_long_term_outcome_of_interstitial_lung_disease_with_anti_aminoacyl_tRNA_synthetase_antibodies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(17)30121-X DB - PRIME DP - Unbound Medicine ER -